Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Satsuma Pharmaceuticals, Inc.
36 subjects received a single dose of STS101, 1.0 mg DHE mesylate IM injection, and 2 mg DHE mesylate nasal spray in a randomized, 5-period crossover manner.
Age
18–50
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
18 to 50 years of age at the time of enrollment.
Signed the informed consent document.
Subject judged to be healthy by a qualified physician
You may not be if
Abnormal physical findings of clinical significance at the screening examination
Significant abnormal laboratory values at the Screening Visit.
Clinically significant symptoms or conditions that may have placed the subject at an unacceptable risk as a participant in the trial, or that may have interfered with the absorption, distribution, metabolism or excretion of the IMP.
